Skip to content
Subscriber Only

Glaxo, Medicago Report Strong Data From Mid-Stage Vaccine Trial

  • Antibodies 10 times higher than recovered Covid-19 patients
  • Companies plan to have data from advanced trials this summer

GlaxoSmithKline Plc and Medicago Inc. said their Covid-19 vaccine candidate spurred protective antibody levels 10 times higher than in patients who have recovered from the disease in interim trial results.

The vaccine generated similar immune responses in all age groups with no serious safety events in the mid-stage trial, Medicago said Tuesday in a statement. About 500 participants ages 18 to 88 received the vaccine, and about 100 got placebo shots.